| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from short-term bank loans | - | 0 |
| Net cash provided by financing activities | 3,488,478 | 2,356,083 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 8,018 | -43,786 |
| Net decrease in cash and cash equivalents and restricted cash | -9,904 | 212,511 |
| Cash and cash equivalents at beginning of period | 863,815 | - |
| Cash and cash equivalents at end of period | 853,911 | - |
ABVC BIOPHARMA, INC. (ABVC)
ABVC BIOPHARMA, INC. (ABVC)